more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$70.37 USD

+0.14 (0.20%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $70.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research Published on August 29,2023

Investors are optimistic about Henry Schein (HSIC), led by the strength of its dental business.

Here's Why Henry Schein (HSIC) is a Strong Value Stock

by Zacks Equity Research Published on August 29,2023

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

HSICPositive Net Change

Henry Schein (HSIC) Q2 Earnings Top, Operating Margin Dips

by Zacks Equity Research Published on August 07,2023

Henry Schein's (HSIC) second quarter 2023 performance demonstrates strength in the North American dental business.

Compared to Estimates, Henry Schein (HSIC) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research Published on August 07,2023

The headline numbers for Henry Schein (HSIC) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

HSICPositive Net Change

Henry Schein (HSIC) Surpasses Q2 Earnings Estimates

by Zacks Equity Research Published on August 07,2023

Henry Schein (HSIC) delivered earnings and revenue surprises of 4.80% and 0.38%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

3 MedTech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas Published on August 03,2023

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

Staar Surgical (STAA) Q2 Earnings Beat Estimates

by Zacks Equity Research Published on August 02,2023

Staar Surgical (STAA) delivered earnings and revenue surprises of 25% and 0.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will High Medical Costs Hurt Cigna (CI) in Q2 Earnings?

by Zacks Equity Research Published on August 01,2023

Cigna's (CI) Q2 results are likely to reflect strength in the specialty pharmacy business and growing medical customer base, partly offset by higher medical expenses.

Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?

by Zacks Equity Research Published on July 28,2023

Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.

Conmed (CNMD) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research Published on July 26,2023

Conmed (CNMD) delivered earnings and revenue surprises of 5.06% and 3.84%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research Published on July 24,2023

West Pharmaceutical's (WST) second-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

medical

What's in the Cards for Universal Health (UHS) in Q2 Earnings?

by Zacks Equity Research Published on July 21,2023

Universal Health's (UHS) Q2 results are likely to benefit from higher patient volumes at its acute care hospitals and behavioral health facilities, partly offset by increased physician expenses.